This is an Active case

Zepbound® Lawsuit

Long-term Zepbound users might experience serious gastrointestinal effects and complications. They may be eligible to file a lawsuit for the harms they experienced.

Connect with an attorney
A young woman is sitting on a couch and has both hands on her stomach. She has her eyes closed and looks very uncomfortable

Case Overview

Zepbound is the brand name for the injectable prescription medication tirzepatide, a dual agonist drug that helps with weight management. Zepbound users have reported serious gastrointestinal issues, including gastroparesis and gastroenteritis. A Zepbound lawsuit filed against manufacturer Eli Lilly could help reimburse lost wages, address pain and suffering and help manage medical expenses.

Important Zepbound lawsuit updates

  • January 2026: The total number of claims in the GLP-1 RA multidistrict litigation (MDL) increased to 3,063.
  • May 2025: The Food and Drug Administration (FDA) published a notice stating its concerns about unapproved GLP-1 RA drugs and instructing patients how to get prescription medications like Zepbound safely. Patients who take unapproved GLP-1 RA drugs may not be able to file a Zepbound lawsuit.
  • January 2025: A study has linked semaglutide and tirzepatide drugs to eye conditions like nonarteritic anterior ischemic optic neuropathy (NAION) and other vision complications.

Key takeaways about the Zepbound Lawsuit

  • Zepbound is an FDA-approved injectable prescription medication used to treat overweight or obese adults.
  • Zepbound users have reported serious gastrointestinal health issues, including gastroparesis and gastroenteritis. Despite disclosing some gastrointestinal side effects, the drug’s manufacturer downplayed the severity of these risks.
  • Lawsuits against Zepbound are proceeding in a multidistrict litigation (MDL) docket in federal courts. The MDL includes claims against Zepbound and its sister drug, Mounjaro®.

What is Zepbound?

Zepbound is an injectable prescription medication with the active ingredient tirzepatide and is manufactured by Eli Lilly. In 2023, the U.S. Food and Drug Administration (FDA) approved Zepbound injections to treat adults who are overweight or obese. Patients must also have at least one weight-related condition, which can include high blood pressure, type 2 diabetes or high cholesterol. Patients are advised to use Zepbound along with a reduced calorie diet and increased physical activity for the greatest effect.

Zepbound is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 receptor agonist (GLP-1 RA). Zepbound works by stimulating hormone receptors in your intestines. This action suppresses a person’s appetite and reduces food intake by creating a feeling of fullness.

Patients typically administer an injection under the skin once per week. Doctors gradually increase the dosage over four to 20 weeks to achieve the highest dosage prescribed for the patient. The maximum dosage an adult can take is 15mg once a week.

How does Zepbound work?

GLP-1 receptor agonists mimic the GLP-1 hormone. Like the hormone it mimics, GLP-1 triggers the pancreas to release insulin into the gastrointestinal tract when a person eats. Insulin helps move glucose from the bloodstream into the body’s cells where it’s used for energy.

When a person has type 2 diabetes, their cells resist insulin or the body doesn’t produce enough insulin. GLP-1 agonists step up and stimulate the pancreas, releasing insulin and preventing another hormone called glucagon from being released. This action helps control blood sugar levels.

A GIP agonist mimics the action of the GIP hormone to enhance insulin secretion when a person has elevated blood glucose levels. This helps the body lower its blood sugar. This agonist can also decrease a person’s appetite.

In medications like Zepbound, a dual agonist approach with GIP and GLP-1 can provide a more comprehensive approach to managing blood sugar and weight.

Health risks of Zepbound

Taking Zepbound for extended periods of time can cause several side effects. Some are more common than others, such as bloating from Zepbound, and some can pose a serious risk to a person’s health.

Common listed Zepbound side effects include:

  • Allergic reactions
  • Belching
  • Constipation
  • Diarrhea
  • Fatigue
  • Hair loss
  • Heartburn
  • Indigestion
  • Injection site reactions
  • Nausea
  • Stomach pain
  • Vomiting

However, additional serious health risks are associated with Zepbound, including:

  • Changes in vision in people with type 2 diabetes
  • Depression or thoughts of suicide
  • Gallbladder problems
  • Inflammation of the pancreas (pancreatitis)
  • Kidney problems caused by dehydration
  • Low blood sugar (hypoglycemia), especially if patients take medications that cause low blood sugar like sulfonylurea or insulin
  • Serious allergic reactions, including problems breathing or swallowing
  • Severe stomach problems

Research has shown that Zepbound causes thyroid C-cell tumors in rats. It isn’t known whether Zepbound has the same effect in humans. If prescribed Zepbound, watch for thyroid cancer symptoms like a lump or swelling in the neck, hoarseness, trouble swallowing or shortness of breath.

If you experience any of these side effects, it’s important to call your healthcare provider or seek immediate medical attention.

Lawsuits against Zepbound

Zepbound’s manufacturer, Eli Lilly, listed gastrointestinal side effects on the drug label. However, these weight loss drug lawsuits claim the manufacturer downplayed the severity of gastrointestinal effects Zepbound users were at risk of developing. This led many patients to pursue legal action against Eli Lilly.

People who have used Zepbound have reported serious gastrointestinal conditions, including gastroparesis and gastroenteritis.

  • Gastroparesis is a dangerous medical condition that can interfere with a person’s digestion. It can cause abdominal pain and severe dehydration. It can also decrease a person’s quality of life because there is no cure for the condition.
  • Gastroenteritis occurs when the stomach and intestines are inflamed. It may cause severe symptoms, such as vomiting, nausea, diarrhea and stomach cramps. Vomiting and nausea can result in dehydration, which is a significant concern because it can lead to complications, including death.

Several Zepbound users have reported being hospitalized because of these conditions. As a result of using the drug, they suffered severe injuries and endured pain and suffering. The hospitalization caused them to incur significant medical expenses.

Contact a GLP-1 RA attorney

If you or a loved one has suffered from a serious side effect that wasn't on the label of a GLP-1 RA drug, you may be eligible to file a lawsuit.

You can also reach our team by calling 1.800.768.4026.

Who is eligible to file a Zepbound lawsuit?

People who have been prescribed Zepbound and have experienced an unlisted or severe health issue may be able to pursue legal action. You might be eligible to file a Zepbound lawsuit if you:

  • Were prescribed Zepbound
  • Followed your doctor’s instructions as directed
  • Developed a serious side effect that wasn’t listed on the label as a risk at the time

You are eligible to file an Eli Lilly lawsuit even if you took the drug for an off-label use as long as the Zepbound medication was prescribed by a doctor and manufactured by Eli Lilly. Motley Rice is actively filing Zepbound lawsuits for those who are eligible.

How to file a Zepbound lawsuit

Zepbound lawsuits against Eli Lilly are in the beginning stages. A Zepbound attorney can help you review your options and prepare your case by:

  • Setting up an initial consultation to review your case
  • Gathering evidence to prove you took Zepbound for weight loss and developed a related, serious health condition
  • Filing your case with the appropriate court

As you prepare to sue the appropriate drug company, gather any paperwork or evidence that is relevant to your case. This may include medical records, prescription details, proof of purchase, documentation of side effects and any correspondence with healthcare providers or the manufacturer.

Zepbound lawsuit news and recent updates

07.01.25

July report showed increase in MDL cases

The GLP-1 RA MDL now has 1,997 pending actions.

06.02.25

June MDL numbers grew

There are now 1,882 pending actions in the GLP-1 MDL.

05.30.25

FDA warned users of unapproved GLP-1 drugs

The FDA published a notice stating their concerns over unapproved GLP-1 medications used for weight loss. They advised patients to obtain a prescription from their doctor and fill that prescription at a state-licensed pharmacy. They also recommended patients visit the FDA BeSafeRx webpage for additional resources to safely buy prescription medications online.

05.01.25

MDL numbers increased leading into May

As of May 2, the GLP-1 MDL rose to 1,809 pending actions.

04.01.25

April report showed MDL case growth

The GLP-1 MDL now has 1,685 pending actions.

03.31.25

Zepbound adverse events reported

The FDA Adverse Event Reporting System (FAERS) reported 15,344 Zepbound adverse events since 2023. This included 730 serious cases and 16 deaths.

03.05.25

Judge halted production of compounded Zepbound

A federal judge issued a decision ruling that compounding pharmacies could no longer make and sell their own versions of Eli Lilly’s drugs Zepbound and Mounjaro.

03.03.25

MDL numbers grew leading into March

There are now 1,521 pending actions in the GLP-1 RA MDL.

02.03.25

February report showed increased MDL numbers

The GLP-1 MDL increased to 1,443 pending actions.

01.30.25

Tirzepatide linked to vision issues and eye conditions

A study published in JAMA Ophthalmology analyzed nine participants taking either semaglutide or tirzepatide drugs. The results of this small study showed that seven patients developed nonarteritic anterior ischemic optic neuropathy (NAION), one developed a stroke in the retina and one patient experienced swelling in both optic nerves.

01.24.25

Novo Nordisk and Eli Lilly tried to dismiss claims

Drug manufacturers Novo Nordisk and Eli Lilly filed a motion to dismiss almost all of the non-gastrointestinal claims in the GLP-1 MDL. This filing didn’t apply to any claims related to the manufacturers not properly warning patients of gastrointestinal issues. Novo Nordisk and Eli Lilly stated that “Plaintiffs fail to translate these broad allegations into viable causes of action for fraud or breach of warranty.”

01.02.25

January MDL numbers grew

As of January 2, there were 1,331 pending actions in the GLP-1 MDL.

12.20.24

Warning label updated to include new risk

The FDA has updated the Zepbound warning label to include information on the increased risk of developing pancreatitis for individuals who are taking Zepbound.

12.02.24

2024 GLP-1 RA MDL numbers

GLP-1 RA MDL pending actions increased dramatically throughout 2024 and are expected to grow into 2025.
December 2024: 1,300 pending actions
November 2024: 1,221 pending actions
October 2024: 1,090 pending actions
September 2024: 869 pending actions
August 2024: 346 pending actions
July 2024: 105 pending actions
June 2024: 101 pending actions
May 2024: 87 pending actions
April 2024: 74 pending actions
March 2024: 58 pending actions

12.01.24

DVT and blood clots not included as injuries in MDL

Deep vein thrombosis (DVT) and blood clot cases will not be included as injuries in In re: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAS) Products Liability Litigation MDL No. 3094. Individuals may still pursue these cases in other venues if they’ve experienced these injuries. Contact GLP-1 RA Motley Rice attorneys Sara Couch or Jonathan Orent.

11.13.24

Plaintiffs filed master complaint in Pennsylvania

Plaintiffs filed a master complaint in the sprawling multidistrict litigation centralized in the Eastern District of Pennsylvania accusing manufacturers Novo Nordisk and Eli Lilly of failing to warn them about the various health risks associated with their medications, including Zepbound.

10.18.24

Zepbound warning label updated with new risk

The warning label on Zepbound and other medications like Ozempic, Wegovy, Rybelsus, Saxenda, Victoza and Mounjaro was updated to include a new warning regarding pulmonary aspiration during general anesthesia or deep sedation.

10.02.24

FDA removed Tirzepatide from drug shortages list

The FDA removed Tirzepatide from the drug shortages list, which may impact availability for patients who were receiving the drug through compounding pharmacies. Drugs made by compounding pharmacies aren’t included in the federal MDL.

05.01.24

Motley Rice attorneys appointed to MDL

Motley Rice attorney Jonathan Orent was named MDL No. 3094 Co-Lead Counsel, and Motley Rice attorney Sara Couch was named Chair of Marketing Discovery, Plaintiffs Executive Committee.

02.15.24

GLP-1 RA MDL is established

Zepbound lawsuits were consolidated with cases against similar drugs in MDL No. 3094, called In re: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAS) Products Liability Litigation.

11.08.23

FDA approved Zepbound for weight management

The FDA approved Zepbound medication for chronic weight management in obese or overweight adults. The Zepbound injection should be used alongside a reduced calorie diet and increased amounts of physical exercise.

View Full Timeline

Frequently asked questions about Zepbound lawsuits

Is there a Zepbound recall?

There isn’t currently a Zepbound recall, but the FDA has provided the public with warnings of counterfeit and compounded versions of Zepbound due to potential safety concerns. Zepbound is still FDA approved for weight management and to improve blood sugar in type 2 diabetes patients.

Is there a Zepbound class action lawsuit?

No. There isn’t a class action suit involving Zepbound side effects. However, lawsuits are proceeding in an MDL docket in federal court. The MDL addresses injuries that arise from using glucagon-like peptide-1 receptor agonists (GLP-1 RAs). Medications involved in this MDL include the Novo Nordisk drugs Ozempic, Rybelsus and Wegovy, and the Eli Lilly and Company drugs Mounjaro, Trulicity and Zepbound.

Does Zepbound cause bowel obstruction?

Zepbound may cause long-term users to develop gastrointestinal issues such as gastroparesis and gastroenteritis, which can lead to bowel obstruction. Symptoms for these serious conditions may include vomiting, nausea, diarrhea and stomach cramps.

What should I do if I've experienced a major adverse event from taking Zepbound?

If you’ve experienced a major adverse event from taking Zepbound, seek medical attention right away. Even if side effects aren’t severe, it’s still important to see a doctor to manage any effects to prevent potential complications.

If you’ve suffered harm after using Zepbound, you may be eligible to file a lawsuit to receive compensation for your injuries. A settlement or verdict from a tirzepatide lawsuit could help pay for medical expenses, lost wages and pain and suffering.

Is Zepbound different from Ozempic and Wegovy?

Zepbound differs from Ozempic and Wegovy in several other ways, including the following:

  • Dual- vs. single-agonist drugs: In addition to the differences in active ingredients, Zepbound targets two hormone receptors as a dual-agonist drug. Wegovy and Ozempic are single-agonist drugs, only mimicking the natural GLP-1 hormone.
  • Manufacturers: U.S.-based Eli Lilly manufactures Zepbound and Mounjaro. Denmark-based Novo Nordisk manufactures Wegovy and Ozempic.
  • Age groups: Zepbound is not approved for use in children, but Ozempic and Wegovy can be prescribed to patients 12 and older for type 2 diabetes management.
  • Dosing schedules and amounts: Zepbound has a starting dosage of 2.5 mg and can be increased to 5 mg once a week with the maximum dosage of 15 mg. Ozempic begins with 0.25 mg and can increase to 0.5 mg once weekly up to 2 mg.

Our medical drug litigation experience

Our prescription drug and device attorneys at Motley Rice have represented thousands of patients harmed by dangerous prescription and over-the-counter drugs. If you believe a weight loss medication like Zepbound injured you or someone you love, our attorneys may be able to help.

Our attorneys will:

  • Investigate whether Zepbound or another weight loss medication may be the cause of your medical issues
  • Review if the manufacturer neglected to warn you about dangerous side effects
  • Identify other issues that could impact your claim

Our medical attorneys are committed to helping you get the justice you and your loved ones deserve.

Read more on our medical drug litigation experience.


Do not stop taking a prescribed medication without first consulting with your doctor. Discontinuing a prescribed medication without your doctor's advice can result in injury or death. Ozempic, Rybelsus, Saxenda, Victoza, Wegovy, Mounjaro, Trulicity and Zepbound remain approved by the U.S. Food and Drug Administration.

Key takeaways

What is Zepbound?

Health risks of Zepbound

Lawsuits against Zepbound

Who is eligible to file a Zepbound lawsuit?

How to file a Zepbound lawsuit

Zepbound lawsuit news and recent updates

Frequently asked questions about Zepbound lawsuits

Our medical drug litigation experience

About the Authors

Sources
  1. Australian Government, Department of Health and Aged Care. Inactive ingredients, the unsung players in medicine.
  2. Eli Lilly. Zepbound Medication Guide.
  3. Fanshier A, Crews B, Garrett M, Johnson J. Tirzepatide: A Novel Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide 1 Receptor Agonist for the Treatment of Type 2 Diabetes: The First Twincretin. Clinical Diabetes. 2023 March: 41(3): 367-377.
  4. Harvard Health Publishing. GLP-1 diabetes and weight-loss drug side effects: “Ozempic face” and more.
  5. The Hill. Federal judge stops compounded copies of Eli Lilly weight loss, diabetes drugs.
  6. Judicial Panel on Multidistrict Litigation. Pending MDLs.
  7. Katz BJ, Lee MS, Lincoff NS. Ophthalmic complications associated with the antidiabetic drugs semaglutide and tirzepatide. JAMA Ophthalmol [Internet]. 2025 Jan 30.
  8. Law.com. Ozempic Defendants Seek to Shave 'Tacked On' Claims From MDL Complaint.
  9. Law.com. Ozempic MDL Plaintiffs Say Eli Lilly, Novo Nordisk Hid Risks.
  10. Mayo Clinic. Tirzepatide (Subcutaneous Route).
  11. Novo Nordisk. Ozempic.
  12. Rodriguez P, Cartwright B, Gratzl S. Semaglutide vs Tirzepatide for Weight Loss in Adults with Overweight or Obesity. JAMA Internal Medicine. 2024 July: 2024.2525.
  13. Sodhi M, Rezaeianzadeh R, Kezouh A. Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss. JAMA. 2023 Oct. 330(18):1795-1797.
  14. UC Health. FDA officials warn of fake weight loss drugs and ban compounded versions of popular medications.
  15. UC Health. What is Zepbound? Does this new weight loss drug work better than Wegovy and Ozempic? Will it cut costs?
  16. U.S. District Court Eastern District of Pennsylvania. IN RE: GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1 RAS) PRODUCTS LIABILITY LITIGATION.
  17. United States District Court, Eastern District of Pennsylvania. MDL 3094 In Re: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAS) Products Liability Litigation.
  18. U.S. Food and Drug Administration. Drug Safety-related Labeling Changes (SrLC).
  19. U.S. Food and Drug Administration. FDA Adverse Events Reporting System (FAERS) Public Dashboard.
  20. U.S. Food and Drug Administration. FDA Approves New Medication for Chronic Weight Management.
  21. U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize.
  22. U.S. Food and Drug Administration. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.
  23. U.S. Judicial Panel on Multidistrict Litigation. Pending MDLs.
  24. Wegovy. Wegovy Dosing Schedule.
  25. Zepbound. What is Zepbound.
  26. Zepbound. Your Weekly Zepbound Routine.
Your Legal Options

Start Your Motley Rice Consultation in Simple Steps

Connect with an Attorney1.800.768.4026

1

Submit Information

Call us or fill out our online form with the details of your potential case.

2

Case Review

Our team reviews your information to assess your potential case.

3

Case Consultation

Talk with us about next steps.